Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment

BACKGROUND: Increased evidences show that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) compared with cytotoxic chemotherapy for metastatic lung nonsquamous cell carcinoma harboring susceptible EGFR mutation, and ge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Onco Targets Ther
Hauptverfasser: Yang, Chih-Jen, Tsai, Ming-Ju, Hung, Jen-Yu, Liu, Ta-Chih, Chou, Shah-Hwa, Lee, Jui-Ying, Hsu, Jui-Sheng, Tsai, Ying-Ming, Huang, Ming-Shyan, Chong, Inn-Wen
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2016
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803239/
https://ncbi.nlm.nih.gov/pubmed/27051298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S100164
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge